Researchers reported promising safety data from an ongoing phase Ib/II clinical trial for SM-88, an investigational combination therapy that might one day offer an alternative to androgen deprivation therapy for men with recurrent, nonmetastatic prostate cancer.
Fewer patients diagnosed with testicular cancer were uninsured, and fewer were diagnosed with late-stage disease, following the Affordable Care Act’s Medicaid enrollment expansion.
Researchers are developing a prognostic hypoxia gene signature for patients with localized prostate cancer that could predict biochemical failure and metastasis.
Enzalutamide resulted in a 71% reduction in metastatic disease risk among men with castration-resistant prostate cancer and rapid prostate-specific antigen doubling time, according to the first interim analysis of data from the phase III PROSPER trial.
A newly developed clinical model can predict overall survival for patients diagnosed with advanced bladder cancer who are treated with atezolizumab.
Adding docetaxel chemotherapy to frontline hormone therapy improves quality of life and may reduce the need for subsequent treatment, according to an analysis from the STAMPEDE trial.
Apalutamide was well-tolerated and associated with delayed metastasis in men with high-risk castration-resistant prostate cancer that has become refractory to conventional hormone therapy, according to an early interim analysis of the phase III SPARTAN clinical trial.
Adding atezolizumab and bevacizumab to standard care was tolerable and slowed tumor growth in patients with previously untreated clear-cell or sarcomatoid-histology metastatic renal cell carcinoma when compared to sunitinib, according to findings from a phase III study.
Last year saw the first two FDA approvals of oncology biosimilars, but experts have voiced concerns about the emerging US biosimilars market, particularly regarding clinical uptake and uncertainty about costs.
Pfizer’s rituximab investigational biosimilar PF-05280586 met the primary endpoint of overall response rate equivalence to rituximab-EU (MabThera) as a frontline treatment for patients diagnosed with CD20-positive follicular lymphoma, the company announced.